Invex Therapeutics Ltd (IXC) is a biopharmaceutical company with a specific focus on the development and commercialization of Exenatide as a treatment for neurological conditions associated with raised intracranial pressure. This pressure can be a serious issue in various neurological conditions, including idiopathic intracranial hypertension, acute stroke, and traumatic brain injury. Invex is working to establish Exenatide, a drug already approved for other uses, as a new and effective treatment option in this area of high unmet medical need.